A randomised controlled crossover pilot study of meropenem standard 30 minute infusion versus prolonged 3 hour infusion in intensive care patients
A study of intensive care patients comparing meropenem 500mg 3 hour infusion versus 1g 30 minute infusion and time above mean inhibitory concentration
Austin Hospital
10 participants
May 16, 2009
Interventional
Conditions
Summary
Meropenem is an antibiotic used in the treatment of serious infections. This study aims to investigate whether giving meropenem a by a longer infusion (3 hours) but a lower dose, enables the antibiotic to be in the bloodstream for at least the same amount of time as a higher dose given over a short time (30 minutes).
Eligibility
Inclusion Criteria3
- Adult intensive care patients
- Sepsis
- Predicted duration of treatment more than 3 days
Exclusion Criteria2
- Predicted duration of treatment < 3 days
- Hypersensitivity to meropenem or other beta-lactams
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Meropenem 500mg administered as a 3 hour infusion. Wash-out period between treatments of at least 24 hours.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12612000284864